Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2351 to 2360 of 2706 total matches.

In Brief: Low-Dose Chlorthalidone (HemiClor) for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025  (Issue 1733)
(Edarbyclor) and atenolol (Tenoretic, and generics).1,2 CHLORTHALIDONE — Chlorthalidone is more potent than ...
The FDA has approved a 12.5-mg tablet formulation of the thiazide-like diuretic chlorthalidone (HemiClor – Ingenus) for treatment of hypertension. Chlorthalidone has been available for years in 15-, 25-, and 50-mg tablets (Thalitone, and generics) and in fixed-dose combinations with azilsartan medoxomil (Edarbyclor) and atenolol (Tenoretic, and generics).
Med Lett Drugs Ther. 2025 Jul 21;67(1733):118   doi:10.58347/tml.2025.1733e |  Show IntroductionHide Introduction

In Brief: Aflibercept (Eylea HD) for Macular Edema Following Retinal Vein Occlusion

   
The Medical Letter on Drugs and Therapeutics • Mar 30, 2026  (Issue 1751)
-related macular degeneration, diabetic macular edema, and diabetic retinopathy.1 A CLINICAL STUDY ...
Eylea HD (Regeneron), which contains 8 mg of the vascular endothelial growth factor (VEGF) inhibitor aflibercept, has now been approved by the FDA for intravitreal treatment of macular edema following retinal vein occlusion (RVO). A 2-mg dose of aflibercept (Eylea) was approved previously for this indication. Eylea and Eylea HD are also approved for treatment of neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
Med Lett Drugs Ther. 2026 Mar 30;68(1751):56   doi:10.58347/tml.2026.1751b |  Show IntroductionHide Introduction

Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
have been reported, particularly after >1 month of use Hyperalgesia, worsening pain that cannot be overcome ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Med Lett Drugs Ther. 2022 Dec 12;64(1665):e199-202 |  Show IntroductionHide Introduction

Drugs of Choice for Cancer

   
Treatment Guidelines from The Medical Letter • Mar 01, 2003  (Issue 7)
. (ISSN 1541-2784) Vol. 1 (Issue 7) March 2003 Published by The Medical Letter, Inc. 1000 Main ...
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer...
Treat Guidel Med Lett. 2003 Mar;1(7):41-52 |  Show IntroductionHide Introduction

The Viralizer For The Common Cold

   
The Medical Letter on Drugs and Therapeutics • Jan 27, 1989  (Issue 784)
or omission. Copyright  1988-2002. The Medical Letter, Inc. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB ...
Recently, full-page advertisements have appeared in the New York Times and other newspapers promoting the Viralizer (Viral Response Systems, Greenwich, CT), a heated nebulizer-sprayer device marketed for treatment of colds, sore throats, allergy and sinusitis symptoms. The device is available without a prescription for about $30 to $40.
Med Lett Drugs Ther. 1989 Jan 27;31(784):8 |  Show IntroductionHide Introduction

Desflurane - A New Volatile Anesthetic

   
The Medical Letter on Drugs and Therapeutics • Apr 30, 1993  (Issue 895)
. Copyright  1988-2002. The Medical Letter, Inc. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http ...
Desflurane (Suprane - Anaquest), an inhalation anesthetic, has been approved by the US Food and Drug Administration for induction and maintenance of general anesthesia in adults and for maintenance of anesthesia in infants and children. Like isoflurane (Forane), the last volatile anesthetic to become available in the USA (Medical Letter, 23:112, 1981), the new agent is a halogenated methyl ethyl ether, differing from isoflurane in the substitution of a fluorine for a chlorine atom.
Med Lett Drugs Ther. 1993 Apr 30;35(895):38-9 |  Show IntroductionHide Introduction

Pallidotomy for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Dec 06, 1996  (Issue 989)
. The Medical Letter, Inc. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http://www.medletter.com ...
Ablation of the globus pallidus, an old treatment for Parkinsons disease, is being tried again, using more refined stereotactic techniques, improved brain imaging and new methods for recording neuronal activity (CW Olanow, Ann Neurol, 40:341, September 1996).
Med Lett Drugs Ther. 1996 Dec 6;38(989):107 |  Show IntroductionHide Introduction

Safety of Dronedarone (Multaq)

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011  (Issue 1379)
for oral treatment of paroxysmal or persistent (non-permanent) atrial fibrillation or atrial flutter.1 ...
Dronedarone (Multaq – Sanofi), an analog of amiodarone, was approved by the FDA in 2009 for oral treatment of paroxysmal or persistent (non-permanent) atrial fibrillation or atrial flutter. Amiodarone (Cordarone, and others) is more effective for this indication, but its use is often limited by its adverse effects, including thyroid and pulmonary toxicity.
Med Lett Drugs Ther. 2011 Dec 12;53(1379):103-4 |  Show IntroductionHide Introduction

Prosthetic Heart Valves

   
The Medical Letter on Drugs and Therapeutics • Aug 20, 2012  (Issue 1397)
than those in the aortic position.1 Mechanical valves are preferred for younger patients ( ...
Prosthetic heart valves have been used effectively in patients with mitral and aortic valvular heart disease for more than 50 years, but no replacement valve developed to date is suitable for all types of patients.
Med Lett Drugs Ther. 2012 Aug 20;54(1397):67 |  Show IntroductionHide Introduction

In Brief: Anktiva for Bladder Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024  (Issue 1705)
) are also approved for the same indication.1 underwent transurethral resection of the tumor before ...
Nogapendekin alfa inbakicept-pmln (Anktiva – ImmunityBio), a first-in-class interleukin-15 (IL15) receptor agonist, has been approved by the FDA for use with Bacillus Calmette-Guérin (BCG) for treatment of patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors. Such patients generally undergo bladder tumor resection, followed by intravesical BCG treatment, but treatment failure and cancer recurrence are common. The adenoviral vector-based intravesical gene therapy nadofaragene firadenovec-vncg (Adstiladrin)...
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e105-6   doi:10.58347/tml.2024.1705e |  Show IntroductionHide Introduction